LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • X4402

    XL-147

    Dual inhibitor of PI3K and mTOR.

    ≥98%
  • E6256

    Epothilone A

    Microtubule depolymerization inhibitor.

    ≥95%
  • C9670

    Cyromazine

    Triazine, melamine derivative, insect growth re...

    ≥98%
  • C822706

    Curvularin

    Macrocyclic lactone.

    ≥98%
  • M5752

    Monastrol

    Pyrimidine derivative; kinesin Eg5 inhibitor.

    ≥95%
  • T7676

    HT-2 Toxin

    Trichothecene mycotoxin produced by Fusarium.

    ≥98%, TLC, HPLC
  • R7680

    Recombinant M. Tuberculosis Antigen TB 38+6+10

    Tuberculosis antigen
  • C3260

    Ciprofibrate

    Fibrate; PPARα agonist.

    ≥98%
  • A5072

    Amsacrine

    Acridine derivative, DNA intercalator; topoisom...

    ≥98%
  • B8275

    n-Butyric Acid

    Fatty acid found in dairy products; HDAC inhibi...

    ≥98%
  • C0273

    Casin

    Cdc42 GTPase inhibitor.

    ≥97%
  • G4581

    Glucosamine Sulfate Potassium Chloride

    Endogenous amino acid sugar involved in cartila...

    ≥98%
  • R3249

    Rimantadine Hydrochloride

    Viral M2 proton channel blocker.

    ≥98%
  • E5210

    Endomorphin-1

    Endogenous opioid peptide; μOr agonist.

    ≥95%
  • C9876

    CYT-387

    JAK2 inhibitor.

    ≥98%
  • C9711

    Cyclovirobuxine D

    Found in Buxus; hERG K+ channel inhibitor.

    ≥97%
  • E325125

    EIDD-2801

    COVID-19 research

    ≥98%
  • F4683

    Fluticasone Propionate

    β2-adrenergic agonist.

    ≥98%
  • V3325

    Virginiamycin M1

    Macrolide antibiotic; peptidyl transferase inhi...

    ≥97%
  • P5745

    Polygalic Acid

    Saponin found in Polygala.

    ≥97%